Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease
Open Access
- 24 May 2025
- journal article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (11) , 3003-3010
Abstract
Background: Inflammatory bowel disease (IBD) is a relapsing-remitting illness requiring proactive monitoring of gut inflammation. We aimed to determine the correlations of plasma myeloperoxidase (pMPO) and calprotectin (pCal), two neutrophil proteins, with existing measures of disease activity. Methods: Adults with IBD undergoing ileocolonoscopy were recruited prospectively. Baseline assessments included blood tests (pMPO, pCal, and C-reactive protein ([CRP]), symptom questionnaires, and endoscopic indices (simple endoscopic score for CD [SES-CD] and UC endoscopic index of severity [UCEIS]). Active IBD was defined as SES-CD > 2 and UCEIS ≥ 2. Spearman’s rank correlations assessed the associations between blood markers and endoscopic activity. The area under the receiver operating characteristics curves (AUROC) and univariable logistic regression assessed the ability of blood markers (at optimal thresholds) to identify active disease. Results: In total, 170 participants were included (female, n = 92; Crohn’s disease [CD], n = 99; median age 46 years, IQR 35-58). Plasma biomarkers more accurately identified active IBD in individuals with UC (AUROCpMPO = 0.76, P < .001; AUROCpCal = 0.66, P < .05; AUROCCRP = 0.73, P < .001) than in CD (AUROCpMPO = 0.62, P > .05; AUROCpCal = 0.65, P < .01; AUROCCRP = 0.66, P < .01). In all patients with IBD, the addition of pCal (AUROC = 0.73, P < .001) and pMPO (AUROC = 0.73, P < .001) to CRP added benefit compared to CRP (AUROC = 0.70, P < .001) alone. Plasma myeloperoxidase > 13.86 ng/mL (odds ratio [OR] = 10.13, 3.4-30.16) and pCal > 961.72 ng/mL (OR = 3.38, 1.21-9.4) were associated with an increased odds of having endoscopically active UC. Conclusions: Plasma MPO shows promise as a potential blood-based biomarker of IBD activity, especially in UC. The combined use of pMPO and CRP adds diagnostic utility in discriminating between active versus quiescent IBD.Keywords
Funding Information
- New Zealand Society of Gastroenterology
- Royal Australasian College of Physicians
This publication has 38 references indexed in Scilit:
- Myeloperoxidase in the inflamed colon: A novel target for treating inflammatory bowel diseaseArchives of Biochemistry and Biophysics, 2018
- C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-AnalysisAmerican Journal of Gastroenterology, 2015
- Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel diseaseInflammatory Bowel Diseases, 2012
- The role of neutrophils during intestinal inflammationMucosal Immunology, 2012
- Endoscopic evaluation of Crohnʼs disease activityInflammatory Bowel Diseases, 2010
- Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's DiseaseClinical Gastroenterology and Hepatology, 2008
- Unravelling the pathogenesis of inflammatory bowel diseaseNature, 2007
- Inflammatory bowel disease: cause and immunobiologyThe Lancet, 2007
- Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CDGastrointestinal Endoscopy, 2004
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980